Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

GlobeNewswire 10 days ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GlobeNewswire May 14, 2025

Emergent BioSolutions Reports First Quarter 2025 Financial Results

GlobeNewswire May 7, 2025

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

GlobeNewswire May 1, 2025

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

GlobeNewswire April 22, 2025

Emergent BioSolutions Announces Stock Repurchase Program

GlobeNewswire March 31, 2025

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

GlobeNewswire March 20, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

GlobeNewswire March 20, 2025

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

GlobeNewswire March 19, 2025

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

GlobeNewswire March 18, 2025

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

GlobeNewswire March 13, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

GlobeNewswire March 12, 2025

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

GlobeNewswire March 10, 2025

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire March 3, 2025

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

GlobeNewswire February 18, 2025

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

GlobeNewswire February 7, 2025

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

GlobeNewswire January 16, 2025

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

GlobeNewswire January 14, 2025

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga(TM) (ansuvimab-zykl) Treatment for Ebola

GlobeNewswire January 13, 2025

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GlobeNewswire January 8, 2025